GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heart Test Laboratories Inc (NAS:HSCS) » Definitions » Cash Flow from Financing

Heart Test Laboratories (Heart Test Laboratories) Cash Flow from Financing : $11.57 Mil (TTM As of Jan. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Heart Test Laboratories Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Jan. 2024, Heart Test Laboratories received $9.18 Mil more from issuing new shares than it paid to buy back shares. It spent $0.05 Mil paying down its debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Heart Test Laboratories earned $9.13 Mil on financial activities for the three months ended in Jan. 2024.


Heart Test Laboratories Cash Flow from Financing Historical Data

The historical data trend for Heart Test Laboratories's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heart Test Laboratories Cash Flow from Financing Chart

Heart Test Laboratories Annual Data
Trend Apr20 Apr21 Apr22 Apr23
Cash Flow from Financing
1.81 2.68 3.84 6.53

Heart Test Laboratories Quarterly Data
Apr20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 1.60 0.32 0.52 9.13

Heart Test Laboratories Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Heart Test Laboratories's Cash from Financing for the fiscal year that ended in Apr. 2023 is calculated as:

Heart Test Laboratories's Cash from Financing for the quarter that ended in Jan. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Heart Test Laboratories  (NAS:HSCS) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Heart Test Laboratories's issuance of stock for the three months ended in Jan. 2024 was $9.18 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Heart Test Laboratories's repurchase of stock for the three months ended in Jan. 2024 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Heart Test Laboratories's net issuance of debt for the three months ended in Jan. 2024 was $-0.05 Mil. Heart Test Laboratories spent $0.05 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Heart Test Laboratories's net issuance of preferred for the three months ended in Jan. 2024 was $0.00 Mil. Heart Test Laboratories paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Heart Test Laboratories's cash flow for dividends for the three months ended in Jan. 2024 was $0.00 Mil. Heart Test Laboratories received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Heart Test Laboratories's other financing for the three months ended in Jan. 2024 was $0.00 Mil. Heart Test Laboratories received $0.00 Mil on other financial activities.


Heart Test Laboratories Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Heart Test Laboratories's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Heart Test Laboratories (Heart Test Laboratories) Business Description

Traded in Other Exchanges
N/A
Address
550 Reserve Street, Suite 360, Southlake, TX, USA, 76092
Heart Test Laboratories Inc is a medical technology company focused on applying innovative AI-based technology to an ECG to expand and improve an ECG's clinical usefulness. The objective of the company is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings.
Executives
David R. Wells director 2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Bruce Bent director 750 BONHAM PARKWAY, LANTANA TX 76226
Mark T Hilz director, officer: See Remarks 3301 DAKOTA DRIVE, NORTHLAKE TX 76226
Patrick Kanouff director 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Brian Szymczak director 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Danielle Watson officer: See Remarks 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Andrew Simpson director, officer: See Remarks 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092